According to our latest study on "Genome Editing Market Size Report, Forecast to 2028 – COVID-19 Impact and Global Analysis – by Technology, Application, and End User,” the market size is projected to reach $16.98 billion by 2028; which was valued at $5.19 billion in 2021 and; it is estimated to register a CAGR of 18.4% from 2021 to 2028. The major players covered in this study are Thermo Fisher Scientific Inc; Merck KGaA; Lonza; Horizon Discovery Group plc; Integrated DNA Technologies; GenScript; New England Biolabs; Eurofins Scientific; CRISPR Therapeutics; Editas Medicine.

Over the past few years, advances in genome editing technologies have been making constant headlines. Genome editing technologies can alter biological research and significantly impact human health, food security, and environmental sustainability since they are precise, relatively inexpensive, easy to use, and remarkably powerful. The advances in genome editing can be traced back to quiet beginnings in the 1990s. The introduction of CRISPR-Cas9—a genome-editing tool that can be used to make precise and targeted changes in the DNA sequence with ease—is mainly responsible for the recent rise in the amount and scope of applications of genome editing technologies. The CRISPR platform's ease of use, as compared to previous technologies, has resulted in its widespread adoption and application. Genome editing could have a favorable impact on sustainable development, environmental management, food security, and the introduction of affordable diagnostics and therapies for various diseases due to these advancements.

A team from MIT and Harvard's Broad Institute has developed a novel CRISPR genome-editing technique that has the potential to fix up to 89% of disease-causing genetic abnormalities. CRISPR-Cas9 and reverse transcriptase, two of the most significant proteins in molecular biology, have been merged into a single machine by researchers. Prime editing is a method that can alter human cells directly in a precise, efficient, and highly versatile manner. They have also developed a CRISPR RNA-cutting enzyme into an antiviral agent that can be programmed to detect and eliminate RNA-based viruses in human cells. The Cas13 enzyme has previously been used to cut and alter human RNA and as a diagnostic approach for detecting the presence of viruses, bacteria, and other targets. This is one of the first studies to use Cas13, or any CRISPR system, as an antiviral in human cells in culture.

Get More info:- https://www.globenewswire.com/en/news-release/2023/06/23/2693885/0/en/18-4-CAGR-for-Genome-Editing-Market-Worth-16-98-Billion-Globally-by-2028-Lead-by-CRISPR-Segment-During-2021-2028-The-Insight-Partners.html

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact US
Contact Person : Ankit Mathur
Phone : +1-646-491-9876
E-mail : [email protected]